| 沙利度胺治疗原发性骨髓纤维化临床疗效观察 |
| |
| 引用本文： | 胡喜梅,周水阳,徐洪,张红,倪君,朱碧辉.沙利度胺治疗原发性骨髓纤维化临床疗效观察[J].中国药物与临床,2004,4(7):507-509. |
| |
| 作者姓名： | 胡喜梅 周水阳 徐洪 张红 倪君 朱碧辉 |
| |
| 作者单位： | 上海市松江区中心医院血液科,201600 |
| |
| 摘 要： | 目的探讨沙利度胺治疗原发性骨髓纤维化(IMF)的临床有效性。方法IMF患者10例,剂量150mg/d,同时羟基脲1.0~3.0mg/d仍维持治疗。根据治疗前后血液学指标白细胞计数、血红蛋白测定、血小板计数和肝脾大小测定的变化及腹胀和下肢浮肿的改善来评定疗效。结果10例脾大患者,9例明显缩小,其中7例巨脾患者5例缩小更显著;2例肝大患者2例恢复正常;5例白细胞升高患者,1例明显降低,2例恢复正常;6例轻中度贫血患者,1例有所上升,2例贫血纠正;4例血小板升高患者,1例明显降低,3例恢复正常。9例腹胀患者,4例好转,3例消失;7例双下肢浮肿患者,2例好转,4例消失。10例IMF患者中,仅2例出现轻度不良反应。结论沙利度胺治疗原发性骨髓纤维化有一定疗效。
|
| 关 键 词： | 沙利度胺 骨髓纤维化 治疗结果 |
| 修稿时间： | 2004年3月25日 |
Clinical efficacy of thalidomide in treatment of patients with idiopathic myelofibrosis |
| |
| HU Xi-mei,ZHOU Shui-yang,XU Hong,ZHANG Hong,NI Jun,ZHU Bi-hui.Clinical efficacy of thalidomide in treatment of patients with idiopathic myelofibrosis[J].Chinese Remedies & Clinics,2004,4(7):507-509. |
| |
| Authors: | HU Xi-mei ZHOU Shui-yang XU Hong ZHANG Hong NI Jun ZHU Bi-hui |
| |
| Institution: | HU Xi-mei,ZHOU Shui-yang,XU Hong,ZHANG Hong,NI Jun,ZHU Bi-hui. Department of Hematology,Shanghai Songjiang District Central Hospital,Shanghai 201600,China |
| |
| Abstract: | Objective To investigate the efficacy of thalidomide in the treatment of patients with idiopathic myelofibrosis (IMF). Methods Ten patients with idiopathic myelofibrosis received the treatment of thalidomide and hydroxyurea ( HU). The dose of thalidomide was administered by 150 mg/d, hydroxyurea was accompanied in all patients. The hematological indicators and other items such as abdominal distension and edema were observed. Results Spleen size decreased in 9/10 and hepar size in 2/2 patients, anemia relieved in 3/6, thrombocytosis in 4/4 and hyperleukocytosis in 3/5 patiens. Abdominal distension alleviated in 7/9, legs edema in 6/7. Mild side effects were seen in 2/10. Conclusion Thalidomide therapy is feasible for patients with idiopathic myelofibrosis |
| |
| Keywords: | Thalidomide Myelofibrosis Treatment outcome |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
